Abstract P6-11-12: Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy

Subgroup Analysis ◽

Disease Burden ◽

Metastatic Breast ◽

Prior Treatment ◽

Phase 2 ◽

Faculty Opinions recommendation of Abstract P6-11-12: Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735553267.793559058 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Subgroup Analysis ◽

Disease Burden ◽

Metastatic Breast ◽

Prior Treatment ◽

Phase 2 ◽

A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer

Cancer ◽

10.1002/cncr.24900 ◽

2010 ◽

Vol 116 (6) ◽

pp. 1440-1445 ◽

Cited By ~ 3

Author(s):

Gabriel N. Hortobagyi ◽

William Heim ◽

Laura Hutchins ◽

Edgardo Rivera ◽

Bernard Mason ◽

...

Keyword(s):

Breast Cancer ◽

Fixed Combination ◽

Metastatic Breast ◽

Daily Regimen ◽

Phase 2 ◽

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.12.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 228-237 ◽

Cited By ~ 1

Author(s):

Noha Rashad ◽

Thoraya Abdelhamid ◽

Samia A. Shouman ◽

Hanan Nassar ◽

Mervat A. Omran ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

First Line Treatment

Abstract OT2-01-21: Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy

10.1158/1538-7445.sabcs16-ot2-01-21 ◽

2017 ◽

Author(s):

JA García-Sáenz ◽

E Carrasco ◽

ML Kneissl ◽

F Zohren ◽

M Martin

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Metastatic Breast ◽

Inhibitor Therapy ◽

Phase 2 ◽

Aromatase Inhibitor Therapy ◽

Phase 2 Study ◽

Er Positive

Abstract P6-15-01: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs16-p6-15-01 ◽

2017 ◽

Cited By ~ 3

Author(s):

S Tolaney ◽

AQ Lam ◽

S Mukundan ◽

S Nanda ◽

J Cox ◽

...

Keyword(s):

Breast Cancer ◽

Renal Function ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Breast Cancer ◽

Abstract P1-14-02: A phase 2 study of low dose metronomic eribulin in metastatic breast cancer

10.1158/1538-7445.sabcs18-p1-14-02 ◽

2019 ◽

Author(s):

P Chalasani ◽

AJ Liu ◽

JA Khanjian ◽

M Peha ◽

BJ Buening ◽

...

Keyword(s):

Breast Cancer ◽

Low Dose ◽

Metastatic Breast ◽

Phase 2 ◽

A phase 2 study of oxaliplatin (O) -capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxane

10.1200/jco.2004.22.90140.705 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 705-705

Author(s):

N. Gebbia ◽

F. Fulfaro ◽

G. Badalamenti ◽

C. Arcara ◽

G. Cicero ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

10.1200/jco.2005.23.16_suppl.564 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 564-564 ◽

Cited By ~ 62

Author(s):

J. T. Carpenter ◽

H. Roché ◽

M. Campone ◽

R. Colomer ◽

A. Jagiello-Gruszfeld ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

10.1200/jco.2014.32.15_suppl.519 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 519-519 ◽

Cited By ~ 3

Author(s):

Joyce O'Shaughnessy ◽

Mario Campone ◽

Etienne Brain ◽

Patrick Neven ◽

Daniel F. Hayes ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast ◽

Abiraterone Acetate ◽

Phase 2 ◽

Phase 2 Study ◽

Estrogen Receptor Positive ◽

Randomized Phase 2

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).

10.1200/jco.2015.33.15_suppl.tps1108 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1108-TPS1108 ◽

Cited By ~ 1

Author(s):

Nicholas C. Turner ◽

Judith Balmaña ◽

Peter A. Fasching ◽

Sara A. Hurvitz ◽

Melinda L. Telli ◽

...

Keyword(s):

Breast Cancer ◽

Brca Mutation ◽

Parp Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study ◽

Germline Brca Mutation